Vaccine

Klick Health Adds 18 Senior Leaders as 27-Year Double-Digit Growth Spurt Continues

Independent health agency continues to attract industry’s brightest minds; fortifies teams companywide as part of commitment to delivering industry-leading innovation,…

2 weeks ago

Sartorius opens new Center of Excellence for bioanalytics in Ann Arbor

Manufacturing of instruments, consumables and reagents for cell and protein analysisConsolidation of existing sites and functions in Ann ArborOverall investment…

2 weeks ago

Moderna’s Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address…

2 weeks ago

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte…

2 weeks ago

Defence’s AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

2 weeks ago

MedAdvisor Solutions Launches Omnichannel Engagement for Pharmacy to Transform Patient Experience, Medication Management

Helping pharmacies deliver smart patient messaging while giving time back to pharmacists WOBURN, Mass., June 5, 2024 /PRNewswire/ -- MedAdvisor Solutions,…

2 weeks ago

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON,…

2 weeks ago

Theralase(R) Technology Effective in Virus Inactivation

TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

2 weeks ago

Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to…

2 weeks ago